AdiposityNCT06223035
Myokine Identification Following Acute Exercise
A study testing Exercise in people with Adiposity, run by Rockefeller University at 1 site in United States.
Trial summary
Exercise stimulates a cascade of responses within the human body. For example, exercise results in the release of proteins into the circulation which communicate with cells and organs throughout the body. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Adiposity
- What is being tested?
- Exercise
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 1 siteUnited States
- Study dates
- 18 Apr 2024to 9 Aug 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- passing the PARQ questionnaire (i.e. answering "NO" to all questions)
- being between the ages of 18-45
- being moderately active (defined as participating in 30 minutes of recreational activity at least once per week for the past 3 months but no more than 3 times per week)
- non-smoking
- free of metabolic or cardiovascular diseases
Who cannot join
- unhealed fractures
- thrombophlebitis (blood clots)
- recent surgery of the upper or lower extremities (any surgeries in past 6 months at the ankle or foot, or in the past year at the knee, hip, shoulder or elbow)
- recent uncontrolled bruising
- recent muscle, bone or joint damage which interferes with regular physical activity
- taking part in vigorous physical activity more than 3 times per week
Show all 13Show fewer
- any prior sensations of chest pain during exercise.
- individuals who are pregnant as determined by an on-site pregnancy test
- individuals who are currently taking exogenous hormones
- individuals who chronically consume NSAIDS or other anti-inflammatory medication (every day for the previous 3 months)
- failing the PARQ questionnaire as indicated by answering "YES" to any of the questions
- Having a BMI >32
- Any medical condition that in the opinion of the investigator will confound interpretation of data for analysis.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Identification of Exercise-induced Myokines Regulating the Muscle-adipose Signaling Axis
Exercise stimulates a cascade of responses within the human body. For example, exercise results in the release of proteins into the circulation which communicate with cells and organs throughout the body. In fact, recent human research identified more than 600 proteins are released into the blood circulation following short-term exercise, many of which are predicted to come from the skeletal muscle and target the fat tissue. However, identification of these muscle-secreted proteins and their target tissue (i.e. fat tissue) remains extremely challenging. This challenge is because tissue needs to be collected from multiple sites (skeletal muscle and fat) and at multiple timepoints (before and after exercise). This study seeks to address these challenges through the collection of fat and blood both before and after short-term exercise followed by protein detection (of the blood) and gene expression (of the fat tissue).
Read the detailed description
Acute exercise stimulates a cascade of responses within the human body. Not only do tissues work in an autonomous manner, but they also secrete factors mediating interorgan communication. Recent human research identified >600 proteins secreted into the circulation following an acute bout of exercise, many of which are predicted to derive from the skeletal muscle and target the adipose tissue. Indeed, human studies have validated the effect exercise-induced myokines have upon adipose physiology, most notably IL-6. While insightful, identification of myokines and their tissue of target (i.e. adipose tissue) remains extremely challenging in humans. This is largely due to the need for tissue collection from multiple sites (skeletal muscle and adipose tissue) and at multiple timepoints (before and after exercise). To address these challenges, This study will implement an acute bout of exercise in a human cohort, followed by tissue collection and in-depth secretome and tissue protein analysis. This study will accomplish these goals through tissue and blood collection at multiple timepoints before and after exercise followed by in-depth proteome and transcriptome analysis.
For the first in-person visit, participants will arrive to The Rockefeller University Hospital between 8:00am to 10:00am in a non-fasted state. All participants will be asked to keep track of their food consumption both the night prior to and the day of the visit. Participants will be asked to consume their breakfast 2-hours prior to arrival, and will be asked to eat their habitual breakfast. Participants will be asked to refrain from intense physical activity 48 hours prior to the testing day, any caffeinated beverages the day of arrival, and any alcoholic beverages for 24-hours prior to arrival.
Height, weight, resting heart rate, blood pressure, and body composition, will be measured. Blood will be collected from the upper arm for blood chemistry analyses including HbA1c (%), Cholesterol (mg/dl), LDL-cholesterol (mg/dl), HDL-cholesterol (mg/dl), Triglyceride (mg/dl), Complete blood count (CBC), and High sensitivity C-reactive protein (hsCRP). An additional 20mL of blood will be drawn from the arm for protein identification through the use of proteomics. Subcutaneous adipose from the lower abdomen will be collected following blood collection.
Following a minimum of one week from fat sample collection, participants will take part in a maximal aerobic consumption (VO2max) test between 8:00am-10:00am. Participants will arrive in a non-fasted state, but all participants will be asked to keep track of their food consumption the night prior to, and the morning of, the VO2max test. When possible, the investigators will recommend the participants to consume the identical dinner/breakfast to that consumed prior to the first in-person visit. Participants will be asked to consume their breakfast 2-hours prior to arrival. Additionally, participants will be asked to refrain from intense physical activity 48 hours prior to the testing day, any caffeinated beverages the day of arrival, and any alcoholic beverages for 24-hours prior to arrival.
For VO2max testing, participants will take part in a general warm up consisting of walking on a motorized treadmill for 5 minutes followed by performing a graded exercise test (GXT) on a motorized treadmill while wearing a one-way, non-rebreathing Hans Rudolph 7450 series V2 mask that allows for the evaluation of all expired air which is calibrated prior to each test. Volume of ventilated expired air as well as oxygen and carbon dioxide concentrations of expired air will be determined using a commercial metabolic cart (Parvo Medics' TrueOne® 2400, Parvo, UT). Specifically, the investigators will incorporate the Ellestad Protocol to determine the participants VO2max. The Ellestad Protocol is divided into 8 phases which gradually increases in speed and incline throughout the test. To confirm that the VO2max test is eliciting a metabolic response, lactate measurements through the use of a finger prick will be taken both before and immediately following the exercise test. Additionally, participants will wear a light-weight heart rate monitoring device (Polar) strapped around the upper torso during testing to track heart rate throughout exercise.
The VO2max test will continue until the participant reaches volitional fatigue defined by reaching a rate of perceived exertion (RPE) greater than 19 (using the Borg RPE Scale), OR a respiratory exchange ratio (RER) reaching above 1.1, OR a participant choosing to cease exercise for any reason.
Blood will be collected from the arm immediately following exercise, 1-hour following the exercise, and 3-hours following exercise. Adipose will be collected Immediately following the final blood draw, participants will be prepped for adipose tissue collection (from the abdominal subcutaneous adipose). This will occur 3-hours following exercise.
- Conditions
- Adiposity
- Being tested
- Exercise
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ExerciseOther
Participants will take part in a VO2max test. This will include a graded exercise test (GXT) on a motorized treadmill while wearing a one-way, non-rebreathing valve and nose clip that allows for the evaluation of all expired air. Specifically, we will incorporate the Ellestad Protocol. The Ellestad Protocol is divided into 8 phases which gradually increases in speed and incline throughout the test. The VO2max test will continue until the participant reaches volitional fatigue defined by reaching a rate of perceived exertion (RPE) greater than 19 (using the Borg RPE Scale), OR a respiratory exchange ratio (RER) reaching above 1.1, OR a participant choosing to cease exercise for any reason.
| Study group | Role | What they receive |
|---|---|---|
| Secretome characterization and signaling to the adipose tissue | Experimental | To identify possible exercise stimulated secreted proteins which signal to the adipose tissue, subcutaneous adipose and blood will be collected both before and at multiple timepoints following a VO2max test. Adipose will be collected from the abdominal subcutaneous region and blood will be collected from the arm. Blood will be analyzed for change in protein abundance and adipose will be analyzed for change in gene expression. Receives: Other: Exercise |
What is being measured
The primary outcome is the main question the study is designed to answer.
Identification and quantification of exercise-induced proteins released into the blood through the use of proteomic analysis.
The change in protein abundance within the circulation will be identified by using proteomic-based detection methods. Proteins detected from the control timepoint (before exercise), will be compared to the three timepoints following exercise.
Measured: Before exercise, immediately following exercise, 1-hour following exercise, 3-hours following exercise
Secondary outcomes (1)
Characterize changes in gene expression of the subcutaneous adipose tissue following exercise through the use of bulk RNA-sequencing.
Bulk RNA-sequencing of subcutaneous adipose tissue will be analyzed both before and following acute exercise. The investigators will seek to identify those genes which show differential gene expression between the pre and post exercise timepoints.
Measured: 1 week pre-intervention, 1-hour following, 3-hours following
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jan 2024
- Study start18 Apr 2024
- Primary completion9 Aug 2024
- Study completion9 Aug 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for AdiposityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rockefeller University
- Sponsor type
- University, hospital or other
- Collaborators
- Hospital for Special Surgery, New York
- Responsible party
- Sponsor
- Investigators
- Luke Olsen, PhD, Principal investigator, The Rockefeller University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06223035
- Sponsor's protocol ID
- LOL-1044
- Status last verified
- Mar 2025
- First submitted
- 30 Nov 2023
- Last updated
- 10 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Walker JM, Garcet S, Aleman JO, Mason CE, Danko D, Butler D, Zuffa S, Swann JR, Krueger J, Breslow JL, Holt PR. Obesity and ethnicity alter gene expression in skin. Sci Rep. 2020 Aug 21;10(1):14079. doi: 10.1038/s41598-020-70244-2.
PubMed 32826922
Study at a glance
From the registry record, last updated by the sponsor on 10 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Identification of Exercise-induced Myokines Regulating the Muscle-adipose Signaling Axis
- ClinicalTrials.gov ID
- NCT06223035
- Acronym / sponsor ID
- LOL-1044
- Conditions
- Adiposity
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 12 participants (actual)
- Lead sponsor
- Rockefeller UniversityUniversity, hospital or other
- Collaborators
- Hospital for Special Surgery, New York
- Study start
- 18 Apr 2024 (actual)
- Primary completion
- 9 Aug 2024 (actual)
- Study completion
- 9 Aug 2024 (actual)
- First posted
- 25 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Exercise stimulates a cascade of responses within the human body. For example, exercise results in the release of proteins into the circulation which communicate with cells and organs throughout the body. In fact, recent human research identified more than 600 proteins are released into the blood circulation following short-term exercise, many of which are predicted to come from the skeletal muscle and target the fat tissue. However, identification of these muscle-secreted proteins and their target tissue (i.e. fat tissue) remains extremely challenging. This challenge is because tissue needs to be collected from multiple sites (skeletal muscle and fat) and at multiple timepoints (before and after exercise). This study seeks to address these challenges through the collection of fat and blood both before and after short-term exercise followed by protein detection (of the blood) and gene expression (of the fat tissue).
Detailed description
Acute exercise stimulates a cascade of responses within the human body. Not only do tissues work in an autonomous manner, but they also secrete factors mediating interorgan communication. Recent human research identified >600 proteins secreted into the circulation following an acute bout of exercise, many of which are predicted to derive from the skeletal muscle and target the adipose tissue. Indeed, human studies have validated the effect exercise-induced myokines have upon adipose physiology, most notably IL-6. While insightful, identification of myokines and their tissue of target (i.e. adipose tissue) remains extremely challenging in humans. This is largely due to the need for tissue collection from multiple sites (skeletal muscle and adipose tissue) and at multiple timepoints (before and after exercise). To address these challenges, This study will implement an acute bout of exercise in a human cohort, followed by tissue collection and in-depth secretome and tissue protein analysis. This study will accomplish these goals through tissue and blood collection at multiple timepoints before and after exercise followed by in-depth proteome and transcriptome analysis.
For the first in-person visit, participants will arrive to The Rockefeller University Hospital between 8:00am to 10:00am in a non-fasted state. All participants will be asked to keep track of their food consumption both the night prior to and the day of the visit. Participants will be asked to consume their breakfast 2-hours prior to arrival, and will be asked to eat their habitual breakfast. Participants will be asked to refrain from intense physical activity 48 hours prior to the testing day, any caffeinated beverages the day of arrival, and any alcoholic beverages for 24-hours prior to arrival.
Height, weight, resting heart rate, blood pressure, and body composition, will be measured. Blood will be collected from the upper arm for blood chemistry analyses including HbA1c (%), Cholesterol (mg/dl), LDL-cholesterol (mg/dl), HDL-cholesterol (mg/dl), Triglyceride (mg/dl), Complete blood count (CBC), and High sensitivity C-reactive protein (hsCRP). An additional 20mL of blood will be drawn from the arm for protein identification through the use of proteomics. Subcutaneous adipose from the lower abdomen will be collected following blood collection.
Following a minimum of one week from fat sample collection, participants will take part in a maximal aerobic consumption (VO2max) test between 8:00am-10:00am. Participants will arrive in a non-fasted state, but all participants will be asked to keep track of their food consumption the night prior to, and the morning of, the VO2max test. When possible, the investigators will recommend the participants to consume the identical dinner/breakfast to that consumed prior to the first in-person visit. Participants will be asked to consume their breakfast 2-hours prior to arrival. Additionally, participants will be asked to refrain from intense physical activity 48 hours prior to the testing day, any caffeinated beverages the day of arrival, and any alcoholic beverages for 24-hours prior to arrival.
For VO2max testing, participants will take part in a general warm up consisting of walking on a motorized treadmill for 5 minutes followed by performing a graded exercise test (GXT) on a motorized treadmill while wearing a one-way, non-rebreathing Hans Rudolph 7450 series V2 mask that allows for the evaluation of all expired air which is calibrated prior to each test. Volume of ventilated expired air as well as oxygen and carbon dioxide concentrations of expired air will be determined using a commercial metabolic cart (Parvo Medics' TrueOne® 2400, Parvo, UT). Specifically, the investigators will incorporate the Ellestad Protocol to determine the participants VO2max. The Ellestad Protocol is divided into 8 phases which gradually increases in speed and incline throughout the test. To confirm that the VO2max test is eliciting a metabolic response, lactate measurements through the use of a finger prick will be taken both before and immediately following the exercise test. Additionally, participants will wear a light-weight heart rate monitoring device (Polar) strapped around the upper torso during testing to track heart rate throughout exercise.
The VO2max test will continue until the participant reaches volitional fatigue defined by reaching a rate of perceived exertion (RPE) greater than 19 (using the Borg RPE Scale), OR a respiratory exchange ratio (RER) reaching above 1.1, OR a participant choosing to cease exercise for any reason.
Blood will be collected from the arm immediately following exercise, 1-hour following the exercise, and 3-hours following exercise. Adipose will be collected Immediately following the final blood draw, participants will be prepped for adipose tissue collection (from the abdominal subcutaneous adipose). This will occur 3-hours following exercise.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Secretome characterization and signaling to the adipose tissue | Experimental | Other: ExerciseTo identify possible exercise stimulated secreted proteins which signal to the adipose tissue, subcutaneous adipose and blood will be collected both before and at multiple timepoints following a VO2max test. Adipose will be collected from the abdominal subcutaneous region and blood will be collected from the arm. Blood will be analyzed for change in protein abundance and adipose will be analyzed for change in gene expression. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- passing the PARQ questionnaire (i.e. answering "NO" to all questions)
- being between the ages of 18-45
- being moderately active (defined as participating in 30 minutes of recreational activity at least once per week for the past 3 months but no more than 3 times per week)
- non-smoking
- free of metabolic or cardiovascular diseases
Key exclusion criteria (13 listed)
- unhealed fractures
- thrombophlebitis (blood clots)
- recent surgery of the upper or lower extremities (any surgeries in past 6 months at the ankle or foot, or in the past year at the knee, hip, shoulder or elbow)
- recent uncontrolled bruising
- recent muscle, bone or joint damage which interferes with regular physical activity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ExerciseParticipants will take part in a VO2max test. This will include a graded exercise test (GXT) on a motorized treadmill while wearing a one-way, non-rebreathing valve and nose clip that allows for the evaluation of all expired air. Specifically, we will incorporate the Ellestad Protocol. The Ellestad Protocol is divided into 8 phases which gradually increases in speed and incline throughout the test. The VO2max test will continue until the participant reaches volitional fatigue defined by reaching a rate of perceived exertion (RPE) greater than 19 (using the Borg RPE Scale), OR a respiratory exchange ratio (RER) reaching above 1.1, OR a participant choosing to cease exercise for any reason. | Other | Secretome characterization and signaling to the adipose tissue |
Primary outcome
Identification and quantification of exercise-induced proteins released into the blood through the use of proteomic analysis.
Time frame: Before exercise, immediately following exercise, 1-hour following exercise, 3-hours following exercise
The change in protein abundance within the circulation will be identified by using proteomic-based detection methods. Proteins detected from the control timepoint (before exercise), will be compared to the three timepoints following exercise.
1 secondary outcome
Characterize changes in gene expression of the subcutaneous adipose tissue following exercise through the use of bulk RNA-sequencing.
Time frame: 1 week pre-intervention, 1-hour following, 3-hours following
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Mar 2025.
- Background: PubMed 32826922Walker JM, Garcet S, Aleman JO, Mason CE, Danko D, Butler D, Zuffa S, Swann JR, Krueger J, Breslow JL, Holt PR. Obesity and ethnicity alter gene expression in skin. Sci Rep. 2020 Aug 21;10(1):14079. doi: 10.1038/s41598-020-70244-2.
- Individual participant dataSharing planned: No
Related trials for Adiposity
Active, not recruiting
Comparing 150cm OAGB With 150cm Biliopancreatic Limb RYGB. A Non-inferiority Trial
Bariatric Surgery Candidate, Obesity
RecruitingPhase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
Not yet recruitingPhase 1
A Study of Safety of SUN-0864 and How it is Processed by and Affects the Body in Healthy Adults and Healthy Adults Who Are Overweight or Obese.
Healthy Participants
Not yet recruiting
Evaluation of the Axomove Therapy Medical Device to Facilitate Adapted Physical Activity for Patients With Obesity
Obese Adults
Not yet recruiting
Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Luke Olsen, PhD principal investigator
The Rockefeller University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Exercise in people with Adiposity, run by Rockefeller University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Identification and quantification of exercise-induced proteins released into the blood through the use of proteomic analysis. (time frame: Before exercise, immediately following exercise, 1-hour following exercise, 3-hours following exercise). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06223035, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2025.